Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
 - EconoTimes)
NEW YORK, March 10, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Horizon Pharma plc (“Horizon” or the “Company”) (Nasdaq:HZNP) in the United States District Court for the Southern District of New York on behalf of a class consisting of all persons or entities who purchased Horizon securities between March 13, 2014 and February 26, 2016, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that Defendants made materially false and misleading statements to investors and/or failed to disclose that: (1) Horizon Pharma’s Prescriptions Made Easy (“PME”) program was set up to artificially inflate the prices of minor differentiation standard retail drugs; (2) sales revenues from drugs sold through Horizon Pharma’s PME program could not be sustained at these inflated price levels; (3) Horizon Pharma’s use of its PME program exposed Horizon Pharma to increased regulatory risks, and (4) as a result, Horizon Pharma’s financial statements were materially false and misleading at all relevant times. When the true details entered the market, the Complaint alleges that the price of the stock dropped sharply and investors suffered damages.
If you wish to serve as lead plaintiff, you must move the Court no later than May 9, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
